Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE

By afschroeder • March 31, 2026

Kileel EM, Malvestutto CD, Zanni MV, Davies-Smith E, Fichtenbaum CJ, Lake JE, Lo J, Aberg JA, Martinez E, Patel K, Bloomfield GS, Chu SM, Awwad A, Diggs MR, Lu AB, Bares SH, Berrner D, Smieja M, Okeke NL, Kumar P, João E, Currier JS, Lu MT, Fox MP, Brennan AT, Douglas PS, Grinspoon SK, Ribaudo HJ. Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE. Lancet HIV. 2026 Mar 27:S2352-3018(25)00354-6. doi: 10.1016/S2352-3018(25)00354-6. Epub ahead of print. PMID: 41911941.

Tags: Infectious Diseases, Publications

Cefadroxil as Oral Transitional Therapy for Gram-Positive Bacteremia With or Without Non-Vertebral Osteomyelitis: A Multicenter Retrospective Cohort Study

Clark DC, Baden R, Banerjee J, Bedrossian R, Chute H, Davar K, Deng D, Donnelly M, Fernandez D, Goodman R, Gordon H, Harris E, Hutcheon[...]

The Cost and Intermediate Cost-Effectiveness of a Randomized Control Trial Delivering U=U Messaging to Increase HIV Testing Among South African Men

Smith PJ, Davey DJ, Schmucker L, Bekker LG, Medina-Marino A, Thirumurthy H, Buttenheim AM, Meyer-Rath G. The Cost and Intermediate Cost-Effectiveness of a Randomized Control[...]

Mpox in advanced AIDS with concurrent opportunistic infections: periprocedural management challenges

Murdande S, Mishra S, Munoz A, Fox K, D'Assumpcao C. Mpox in advanced AIDS with concurrent opportunistic infections: periprocedural management challenges. Infect Prev Pract. 2026[...]